IRIS Accounts Production v24.3.2.46 06348778 Board of Directors Board of Directors 1.4.23 31.3.24 31.3.24 true false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh063487782023-03-31063487782024-03-31063487782023-04-012024-03-31063487782022-03-31063487782022-04-012023-03-31063487782023-03-3106348778ns15:EnglandWales2023-04-012024-03-3106348778ns14:PoundSterling2023-04-012024-03-3106348778ns10:Director12023-04-012024-03-3106348778ns10:Director22023-04-012024-03-3106348778ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3106348778ns10:SmallEntities2023-04-012024-03-3106348778ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3106348778ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3106348778ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3106348778ns10:FullAccounts2023-04-012024-03-310634877812023-04-012024-03-3106348778ns10:OrdinaryShareClass12023-04-012024-03-3106348778ns10:Director32023-04-012024-03-3106348778ns10:Director42023-04-012024-03-3106348778ns10:Director52023-04-012024-03-3106348778ns10:Director62023-04-012024-03-3106348778ns10:CompanySecretary12023-04-012024-03-3106348778ns10:RegisteredOffice2023-04-012024-03-3106348778ns5:CurrentFinancialInstruments2024-03-3106348778ns5:CurrentFinancialInstruments2023-03-3106348778ns5:ShareCapital2024-03-3106348778ns5:ShareCapital2023-03-3106348778ns5:RetainedEarningsAccumulatedLosses2024-03-3106348778ns5:RetainedEarningsAccumulatedLosses2023-03-3106348778ns5:PatentsTrademarksLicencesConcessionsSimilar2023-04-012024-03-3106348778ns5:ComputerEquipment2023-04-012024-03-3106348778ns5:PatentsTrademarksLicencesConcessionsSimilar2023-03-3106348778ns5:PatentsTrademarksLicencesConcessionsSimilar2024-03-3106348778ns5:PatentsTrademarksLicencesConcessionsSimilar2023-03-3106348778ns5:ComputerEquipment2023-03-3106348778ns5:ComputerEquipment2024-03-3106348778ns5:ComputerEquipment2023-03-3106348778ns5:CostValuation2023-03-3106348778ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3106348778ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3106348778ns10:OrdinaryShareClass12024-03-31
REGISTERED NUMBER: 06348778 (England and Wales)




















Unaudited Financial Statements

for the Year Ended 31 March 2024

for

Ilex Health Products Ltd

Ilex Health Products Ltd (Registered number: 06348778)






Contents of the Financial Statements
for the year ended 31 March 2024




Page

Company Information 1

Balance Sheet 2 to 3

Notes to the Financial Statements 4 to 7


Ilex Health Products Ltd

Company Information
for the year ended 31 March 2024







DIRECTORS: Mr A J Nolan
Mr W J Nolan
Mr V Smears
Mrs B Smears
Mrs K A Nolan
Mrs M A Nolan





SECRETARY: Mrs B Smears





REGISTERED OFFICE: Unit 2, Brookfield
Duncan Close
Moulton Park
Northampton
Northamptonshire
NN3 6WL





REGISTERED NUMBER: 06348778 (England and Wales)





ACCOUNTANTS: Clifford Roberts
Chartered Accountants
Pacioli House
9 Brookfield
Duncan Close
Northampton
Northamptonshire
NN3 6WL

Ilex Health Products Ltd (Registered number: 06348778)

Balance Sheet
31 March 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 - -
Investments 6 59 59
59 59

CURRENT ASSETS
Stocks - 47
Debtors 7 50,853 220,247
Cash at bank and in hand 81,096 35,966
131,949 256,260
CREDITORS
Amounts falling due within one year 8 101,961 16,427
NET CURRENT ASSETS 29,988 239,833
TOTAL ASSETS LESS CURRENT
LIABILITIES

30,047

239,892

CAPITAL AND RESERVES
Called up share capital 10 2 2
Retained earnings 30,045 239,890
SHAREHOLDERS' FUNDS 30,047 239,892

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Ilex Health Products Ltd (Registered number: 06348778)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 14 March 2025 and were signed on its behalf by:




Mr A J Nolan - Director



Mr W J Nolan - Director


Ilex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements
for the year ended 31 March 2024

1. STATUTORY INFORMATION

Ilex Health Products Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are presented in Sterling (£) and cover the period to 31st March each year. As of 31st March 2024 the company has ceased trading, the company will remain in existence while it deals with its affairs.

Preparation of consolidated financial statements
The financial statements contain information about Ilex Health Products Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover is recognised on the shipment of the product being sold after an order is placed by a customer.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences have been amortised over their estimated useful life of 3 years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 25% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Ilex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost.

Interest bearing borrowings
Interest bearing borrowings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, interest bearing borrowings are stated at amortised cost with any difference between the amount initially recognised and redemption value being recognised in the statement of comprehensive income over the period of the borrowings, together with any interest and fees payable, using the effective interest method.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2023 - 8 ) .

Ilex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

4. INTANGIBLE FIXED ASSETS
Patents
and
licences
£   
COST
At 1 April 2023
and 31 March 2024 75,486
AMORTISATION
At 1 April 2023
and 31 March 2024 75,486
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

5. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 April 2023
and 31 March 2024 23,790
DEPRECIATION
At 1 April 2023
and 31 March 2024 23,790
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 April 2023
and 31 March 2024 59
NET BOOK VALUE
At 31 March 2024 59
At 31 March 2023 59

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors - 15,504
Amounts owed by group undertakings - 197,816
Other debtors 50,853 6,927
50,853 220,247

Ilex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 6,656 5,188
Amounts owed to group undertakings 43,030 -
Taxation and social security - 4,487
Other creditors 52,275 6,752
101,961 16,427

9. FINANCIAL INSTRUMENTS

The company has some exposure to foreign currency, credit, liquidity and cash flow interest rate risks, These risks are limited by the company's financial management policies and practices described below.

Foreign currency risk
The company maintains both a euro account and a dollar account, so that the timing of any financial currency exchanges can be monitored and undertaken at an opportune time ensuring foreign currency risk is mitigated as far as practical.

Credit risk
The company's exposure and it's customers credit worthiness is continually monitored so that any potential problems are detected at an early stage. The majority of the company's sales receipts are received at order which vastly reduces credit risk.

Liquidity risk
The directors have ultimate responsibility for liquidity risk management in maintaining adequate reserves and banking facilities. This is less of an issue due to immediate customer receipts than it could potentially have been.

Market risk
There is a market risk associated with the fluctuation in demand for the products and services provided. Most of this is mitigated by monitoring the markets and acting accordingly.

The company holds no derivative financial instruments at the year end.

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
2 Ordinary £1 2 2

11. RELATED PARTY DISCLOSURES

During the year the company has traded with related parties, The costs incurred, including rent, insurances and other costs, were charged totalling £97,475 (2023 - £15,273). The creditor outstanding at the year end was £6,000 (2023 - £nil)

12. ULTIMATE CONTROLLING PARTY

The ultimate parent company and controlling party is Brookfield VTW Limited, a company registered in England and registered office being Unit 2, Brookfield, Duncan Close, Moulton Park, Northampton, NN3 6WL.